201 related articles for article (PubMed ID: 34030459)
21. Virologic outcomes among adults with HIV using integrase inhibitor-based antiretroviral therapy.
Lu H; Cole SR; Westreich D; Hudgens MG; Adimora AA; Althoff KN; Silverberg MJ; Buchacz K; Li J; Edwards JK; Rebeiro PF; Lima VD; Marconi VC; Sterling TR; Horberg MA; Gill MJ; Kitahata MM; Eron JJ; Moore RD;
AIDS; 2022 Feb; 36(2):277-286. PubMed ID: 34934020
[TBL] [Abstract][Full Text] [Related]
22. Trends and factors associated with modification or discontinuation of the initial antiretroviral regimen during the first year of treatment in the Turkish HIV-TR Cohort, 2011-2017.
Korten V; Gökengin D; Eren G; Yıldırmak T; Gencer S; Eraksoy H; Inan D; Kaptan F; Dokuzoğuz B; Karaoğlan I; Willke A; Gönen M; Ergönül Ö;
AIDS Res Ther; 2021 Jan; 18(1):4. PubMed ID: 33422112
[TBL] [Abstract][Full Text] [Related]
23. Clinical Effectiveness of Integrase Strand Transfer Inhibitor-Based Antiretroviral Regimens Among Adults With Human Immunodeficiency Virus: A Collaboration of Cohort Studies in the United States and Canada.
Lu H; Cole SR; Westreich D; Hudgens MG; Adimora AA; Althoff KN; Silverberg MJ; Buchacz K; Li J; Edwards JK; Rebeiro PF; Lima VD; Marconi VC; Sterling TR; Horberg MA; Gill MJ; Kitahata MM; Eron JJ; Moore RD
Clin Infect Dis; 2021 Oct; 73(7):e1408-e1414. PubMed ID: 32780095
[TBL] [Abstract][Full Text] [Related]
24. First-line HIV treatment outcomes following the introduction of integrase inhibitors in UK guidelines.
El Bouzidi K; Jose S; Phillips AN; Pozniak A; Ustianowski A; Gompels M; Winston A; Schaap A; Dunn DT; Sabin CA;
AIDS; 2020 Oct; 34(12):1823-1831. PubMed ID: 32516283
[TBL] [Abstract][Full Text] [Related]
25. Virological and immunological impact of integrase inhibitor-based regimens initiated during primary HIV-1 infection.
Veil R; Poizot-Martin I; Reynes J; Goujard C; Seng R; Delobel P; Cotte L; Duvivier C; Rey D; Tran L; Surgers L; Allavena C; Lascoux Combe C; Cheret A; Meyer L
AIDS; 2020 Mar; 34(4):493-500. PubMed ID: 31764069
[TBL] [Abstract][Full Text] [Related]
26. Emergent drug resistance with integrase strand transfer inhibitor-based regimens.
Lepik KJ; Harrigan PR; Yip B; Wang L; Robbins MA; Zhang WW; Toy J; Akagi L; Lima VD; Guillemi S; Montaner JSG; Barrios R
AIDS; 2017 Jun; 31(10):1425-1434. PubMed ID: 28375875
[TBL] [Abstract][Full Text] [Related]
27. Integrase strand-transfer inhibitor use and cardiovascular events in adults with HIV: an emulation of target trials in the HIV-CAUSAL Collaboration and the Antiretroviral Therapy Cohort Collaboration.
Rein SM; Lodi S; Logan RW; Touloumi G; Antoniadou A; Wittkop L; Bonnet F; van Sighem A; van der Valk M; Reiss P; Klein MB; Young J; Jarrin I; d'Arminio Monforte A; Tavelli A; Meyer L; Tran L; Gill MJ; Lang R; Surial B; Haas AD; Justice AC; Rentsch CT; Phillips A; Sabin CA; Miro JM; Trickey A; Ingle SM; Sterne JAC; Hernán MA;
Lancet HIV; 2023 Nov; 10(11):e723-e732. PubMed ID: 37923486
[TBL] [Abstract][Full Text] [Related]
28. Effects of first-line antiretroviral therapy on the CD4/CD8 ratio and CD8 cell counts in CoRIS: a prospective multicentre cohort study.
Serrano-Villar S; Martínez-Sanz J; Ron R; Talavera-Rodríguez A; Fernández-Felix BM; Herrera S; Muriel A; Fanjul F; Portilla J; Muñoz J; Amador C; de Zárraga MA; Vivancos MJ; Moreno S;
Lancet HIV; 2020 Aug; 7(8):e565-e573. PubMed ID: 32763219
[TBL] [Abstract][Full Text] [Related]
29. Antiretroviral Therapy Anchor-based Trends in Body Mass Index Following Treatment Initiation Among Military Personnel with HIV.
Kline MDA; Daniels C; Xu X; Sunil T; Ganesan A; Agan BK; Colombo RE; Kronmann KC; Blaylock JM; Okulicz JF; Markelz AE
Mil Med; 2021 Feb; 186(3-4):279-285. PubMed ID: 33128552
[TBL] [Abstract][Full Text] [Related]
30. Risk of Incident Diabetes Mellitus, Weight Gain, and Their Relationships With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among Persons With Human Immunodeficiency Virus in the United States and Canada.
Rebeiro PF; Jenkins CA; Bian A; Lake JE; Bourgi K; Moore RD; Horberg MA; Matthews WC; Silverberg MJ; Thorne J; Mayor AM; Lima VD; Palella FJ; Saag MS; Althoff KN; Gill MJ; Wong C; Klein MB; Crane HM; Marconi VC; Shepherd BE; Sterling TR; Koethe JR
Clin Infect Dis; 2021 Oct; 73(7):e2234-e2242. PubMed ID: 32936919
[TBL] [Abstract][Full Text] [Related]
31. Rapid ART start in early HIV infection: Time to viral load suppression and retention in care in a London cohort.
Girometti N; Lander F; McOwan A; Nwokolo N; Boffito M; Whitlock G;
HIV Med; 2020 Oct; 21(9):613-615. PubMed ID: 32869951
[TBL] [Abstract][Full Text] [Related]
32. Outcomes of Integrase Inhibitor-based Antiretroviral Therapy in a Clinical Cohort of Treatment-experienced Children, Adolescents and Young Adults With HIV Infection.
Levy ME; Griffith C; Ellenberger N; Monroe AK; Castel AD; Rakhmanina N;
Pediatr Infect Dis J; 2020 May; 39(5):421-428. PubMed ID: 32176183
[TBL] [Abstract][Full Text] [Related]
33. Real-world medication persistence among HIV-1 patients initiating integrase inhibitor-based antiretroviral therapy in Japan.
Wang X; Schmerold L; Naito T
J Infect Chemother; 2022 Nov; 28(11):1464-1470. PubMed ID: 35850403
[TBL] [Abstract][Full Text] [Related]
34. Immunological and virological efficacy of different antiretroviral regimens initiated during acute/recent HIV infection.
Ambrosioni J; Farrera J; de Lazzari E; Nicolás D; Manzardo C; Hernández-Meneses MM; Mosquera MM; Ligero C; Marcos MA; Sánchez-Palomino S; Fernández E; Plana M; Miró JM;
AIDS; 2020 Dec; 34(15):2269-2274. PubMed ID: 32910066
[TBL] [Abstract][Full Text] [Related]
35. Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Gianotti N; Lorenzini P; Cozzi-Lepri A; De Luca A; Madeddu G; Sighinolfi L; Pinnetti C; Santoro C; Meraviglia P; Mussini C; Antinori A; d'Arminio Monforte A;
J Antimicrob Chemother; 2019 Sep; 74(9):2732-2741. PubMed ID: 31173639
[TBL] [Abstract][Full Text] [Related]
36. Which antiretrovirals should be prescribed as first-line treatments? Changes over the past 10 years in France.
Pugliese P; Joly V; Valantin MA; Cotte L; Huleux T; Allavena C; Reynes J; Poizot-Martin I; Bani-Sadr F; Cuzin L;
Med Mal Infect; 2019 Jun; 49(4):264-269. PubMed ID: 30409541
[TBL] [Abstract][Full Text] [Related]
37. Integrase Inhibitors Use and Cytomegalovirus Infection Predict Immune Recovery in People Living With HIV Starting First-Line Therapy.
Fabbiani M; Borghetti A; Squillace N; Colafigli M; Taramasso L; Lombardi A; Rossetti B; Ciccullo A; Colella E; Picarelli C; Berruti M; Latini A; Montagnani F; Sambo M; Di Biagio A; Gori A; Di Giambenedetto S; Bandera A
J Acquir Immune Defic Syndr; 2021 Jan; 86(1):119-127. PubMed ID: 33306566
[TBL] [Abstract][Full Text] [Related]
38. Comparative efficacy and safety of dolutegravir relative to common core agents in treatment-naïve patients infected with HIV-1: a systematic review and network meta-analysis.
Snedecor SJ; Radford M; Kratochvil D; Grove R; Punekar YS
BMC Infect Dis; 2019 May; 19(1):484. PubMed ID: 31146698
[TBL] [Abstract][Full Text] [Related]
39. Integrase strand transfer inhibitor-based regimen is related with a limited HIV-1 V3 loop evolution in clinical practice.
Alteri C; Scutari R; Bertoli A; Armenia D; Gori C; Fabbri G; Mastroianni CM; Cerva C; Cristaudo A; Vicenti I; Bruzzone B; Zazzi M; Andreoni M; Antinori A; Svicher V; Ceccherini-Silberstein F; Perno CF; Santoro MM
Virus Genes; 2019 Jun; 55(3):290-297. PubMed ID: 30796743
[TBL] [Abstract][Full Text] [Related]
40. Brief Report: Weight Gain in Persons With HIV Switched From Efavirenz-Based to Integrase Strand Transfer Inhibitor-Based Regimens.
Norwood J; Turner M; Bofill C; Rebeiro P; Shepherd B; Bebawy S; Hulgan T; Raffanti S; Haas DW; Sterling TR; Koethe JR
J Acquir Immune Defic Syndr; 2017 Dec; 76(5):527-531. PubMed ID: 28825943
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
